Design-Outcome Concordance in Targeted-Therapy Trials in Non-Small Cell Lung Cancer: A Meta-Analysis
Trial design choices significantly bias treatment benefit estimates in lung cancer, highlighting need for better standards in precision oncology.
This JNCI meta-analysis quantifies how closely clinical trial design features map onto observed outcomes across NSCLC targeted therapy trials, identifying design-specific biases that affect treatment benefit estimates. Findings have immediate implications for trial design standards, regulatory approval thresholds, and the interpretation of existing NSCLC precision oncology evidence.
What the study was
- Study design
- Systematic review and meta-analysis
- Population
- NSCLC patients enrolled in biomarker-selected targeted therapy clinical trials
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Journal of the National Cancer Institute
Why it surfaced
JNCI meta-analysis on NSCLC targeted therapy trial design concordance; informs precision oncology evidence quality interpretation at field-level scale.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.